Showing results (681-690 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 2, 2014
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cellsNicole Grabinski, Florian Ewald
Investigational New Drugs|August 14, 2014
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsA Craig Lockhart, Shankar Sundaram, John Sarantopoulos, et al.
Investigational New Drugs|August 15, 2014
Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumorsMélodie Carbonnaux, Yann Molin, Pierre-Jean Souquet, et al.
Investigational New Drugs|December 6, 2013
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignanciesSiqing Fu, Ming-Mo Hou, Jennifer Wheler, et al.
Investigational New Drugs|January 4, 2012
Using the neurotransmitter serotonin to target imaging agents to glioblastoma cellsAlexander Sturzu, Sumbla Sheikh, Uwe Klose, et al.
Investigational New Drugs|December 22, 2011
A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinomaTakuji Okusaka, Hiroshi Kasugai, Hiroshi Ishii, et al.
Investigational New Drugs|January 10, 2013
Vascular disrupting effect of CKD-516: preclinical study using DCE-MRIKyung Won Kim, Jeong Min Lee, Yong Sik Jeon, et al.
Investigational New Drugs|January 15, 2013
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcomaAndrew Poklepovic, Leena E Youssefian, Leena Youseffian, et al.
Investigational New Drugs|January 15, 2013
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgeryNigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, et al.
Investigational New Drugs|January 15, 2013
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPASerena Marchetti, Dick Pluim, Monique van Eijndhoven, et al.
Pageof 372